Knight Therapeutics Celebrates 10 Years of Success and Growth

Knight Therapeutics Inc. (TSX: GUD), a leading Pan American specialty pharmaceutical company, is marking a significant milestone as it celebrates its 10th anniversary. Over the past decade, Knight has demonstrated remarkable growth and expansion, solidifying its position as a key player in the pharmaceutical industry across Canada and Latin America.

Knight’s commitment to innovation is evident through its investment of over $925 million in developing a distinctive Pan-American platform for pharmaceutical products. With a workforce of more than 700 skilled employees operating in Canada and 10 Latin American markets, Knight has established itself as a fully integrated company with expertise in various key areas.

The company’s dedication to excellence is reflected in its financial performance, with record revenues and EBITDA reported consistently since 2014. In the third quarter of 2023 alone, Knight achieved year-over-year revenues exceeding $335 million and adjusted EBITDA surpassing $61 million. This success underscores Knight’s robust growth trajectory and financial stability.

Knight’s reputation as a preferred partner for biotechnology and pharmaceutical companies is underscored by its centralized solution across 11 territories. Following the acquisition of Grupo Biotoscana, Knight has secured 11 new partnerships for 13 innovative products. Additionally, the company boasts a diverse portfolio of 17 products set to generate over $120 million in revenues, showcasing its commitment to product development and market expansion.

Jonathan Ross Goodman, Chairman of the Board of Directors at Knight, expressed pride in the company’s achievements, emphasizing their dedication to providing high-quality pharmaceutical products to the Canadian and Latin American populations. Similarly, Samira Sakhia, President and CEO of Knight, commended the exceptional teams across all countries for their unwavering commitment to patient care, positioning Knight as a trusted partner in healthcare.

As Knight Therapeutics looks ahead to the future, its legacy of success and innovation serves as a testament to its ongoing commitment to delivering value to shareholders and partners alike. With a strong foundation built over the past decade, Knight is poised for continued growth and success in the dynamic pharmaceutical landscape.

By celebrating a decade of accomplishments, Knight Therapeutics reaffirms its position as a leader in the pharmaceutical industry, driven by a vision of excellence and a dedication to improving healthcare outcomes for communities across Canada and Latin America.